{
    "clinical_study": {
        "@rank": "80501", 
        "arm_group": [
            {
                "arm_group_label": "Sitagliptin + Metformin XR FDC", 
                "arm_group_type": "Experimental", 
                "description": "Phase A: two sitagliptin + extended-release (XR) metformin fixed-dose combination (FDC) tablets (MK-0431A XR) orally daily (total daily dose: 100 mg sitagliptin and 1000, 1500 or 2000 mg metformin XR) plus two placebo to metformin XR tablets for 20 weeks. Insulin glargine may be administered as glycemic rescue therapy during Phase A of the study. Phase B: two sitagliptin + metformin XR FDC tablets orally daily (total daily dose: 100 mg sitagliptin and 1000, 1500 or 2000 mg metformin XR) plus two placebo to metformin XR tablets for 34 weeks. Insulin glargine may be administered during Phase B of the study depending on the participants' glucose and A1C levels."
            }, 
            {
                "arm_group_label": "Placebo to Sitagliptin + Metformin XR FDC", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Phase A: two placebo to sitagliptin + metformin XR FDC tablets orally daily plus two metformin XR tablets (total daily dose: 1000, 1500 or 2000 mg) for 20 weeks. Insulin glargine may be administered as glycemic rescue therapy during Phase A of the study. Phase B: two placebo to sitagliptin + metformin XR FDC tablets orally daily plus two metformin XR tablets (total daily dose: 1000, 1500 or 2000 mg) for 34 weeks. Insulin glargine may be administered during Phase B of the study depending on the participants' glucose and A1C levels."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and efficacy of the addition of\n      sitagliptin (administered as MK-0431A XR) compared with the addition of placebo to therapy\n      with extended-release metformin (metformin XR) for the treatment of type 2 diabetes mellitus\n      (T2DM) in pediatric participants with inadequate glycemic control on metformin monotherapy.\n      The primary hypothesis is that the addition of sitagliptin reduces hemoglobin A1c (A1C) more\n      than the addition of placebo after 20 weeks of treatment."
        }, 
        "brief_title": "A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289)", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has T2DM\n\n          -  Has not received treatment with insulin for at least 12 weeks prior to study\n             participation\n\n          -  A1C greater than or equal to 6.5% and less than or equal to 10.0% on metformin\n             immediate release (IR) or extended release (XR), greater than or equal to 1500\n             mg/day, for greater than or equal to 12 weeks. NOTE: Participants on a daily dose of\n             metformin greater than or equal to 1000 mg/day, but less than 1500 mg/day for greater\n             than or equal to 12 weeks may be eligible if there is documentation that higher doses\n             are not tolerated.\n\n          -  Between 10 and 17 years of age (inclusive)\n\n          -  Male, or female who is unlikely to conceive (non-sterilized, and is not sexually\n             active or agrees to abstain from heterosexual activity or agrees to use an adequate\n             method of contraception) during the study and for 14 days after the last dose of\n             study drug\n\n        Exclusion Criteria:\n\n          -  Has type 1 diabetes mellitus\n\n          -  Has monogenic diabetes or secondary diabetes\n\n          -  Has previously taken a dipeptidyl peptidase IV (DPP-4) inhibitor (such as\n             sitagliptin, vildagliptin, alogliptin, saxagliptin, or linagliptin) or glucagon-like\n             peptide-1 (GLP-1) receptor agonist (such as exenatide or liraglutide)\n\n          -  Is on or likely to require treatment for > or =2 consecutive weeks or repeated\n             courses of corticosteroids (inhaled, nasal and topical corticosteroids are permitted)\n\n          -  Has undergone a surgical procedure within 4 weeks of study participation or has\n             planned major surgery during the study\n\n          -  History of congenital heart disease or cardiovascular disease other than hypertension\n\n          -  History of active liver disease (other than non-alcoholic steatosis), including\n             chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic\n             gallbladder disease\n\n          -  Active neuropathy (such as nephrotic syndrome or glomerulonephritis)\n\n          -  Chronic myopathy, mitochondrial disorder or a progressive neurological or\n             neuromuscular disorder\n\n          -  Human immunodeficiency virus (HIV)\n\n          -  Hematological disorder (such as aplastic anemia, thrombocytopenia, myeloproliferative\n             or myelodysplastic syndromes)\n\n          -  Is currently being treated for hyperthyroidism or is on thyroid hormone therapy and\n             has not been on a stable dose for at least 6 weeks\n\n          -  History of malignancy for < or =5 years prior to study participation, except for\n             adequately treated basal cell or squamous cell skin cancer, or in situ cervical\n             cancer\n\n          -  History of idiopathic acute pancreatitis or chronic pancreatitis\n\n          -  History of recreational or illicit drug use, or of alcohol abuse or\n\n        dependence (within the past year)\n\n          -  Has donated blood products or has had phlebotomy of >10% of estimated\n\n        total blood volume within 8 weeks of study participation, or intends to donate\n\n        blood products or receive blood products within the projected duration of the study\n\n          -  Is pregnant or breast-feeding, or is expecting to conceive or donate eggs during the\n             study, including 14 days following the last dose of study drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01760447", 
            "org_study_id": "0431A-289", 
            "secondary_id": "2012-004035-23"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sitagliptin + Metformin XR FDC", 
                "description": "Sitagliptin + Metformin XR fixed-dose combination tablet (sitagliptin/metformin: 50/500 mg, 50/1000 mg) administered with a meal, preferably in the evening", 
                "intervention_name": "Sitagliptin + Metformin XR FDC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo to Sitagliptin + Metformin XR FDC", 
                "description": "Matching placebo to Sitagliptin + Metformin XR fixed-dose combination tablet administered with a meal, preferably in the evening", 
                "intervention_name": "Placebo to Sitagliptin + Metformin XR", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo to Sitagliptin + Metformin XR FDC", 
                "description": "Metformin XR tablet (500 mg, 1000 mg) administered with a meal, preferably in the evening", 
                "intervention_name": "Metformin XR", 
                "intervention_type": "Drug", 
                "other_name": "Glucophage\u00ae XR"
            }, 
            {
                "arm_group_label": "Sitagliptin + Metformin XR FDC", 
                "description": "Matching placebo to metformin XR tablet administered with a meal, preferably in the evening", 
                "intervention_name": "Placebo to metformin XR", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sitagliptin + Metformin XR FDC", 
                    "Placebo to Sitagliptin + Metformin XR FDC"
                ], 
                "description": "The insulin regimen and dosing will be at the discretion of the investigator (based on locally accepted, national, or international guidelines for the indication and use of insulin glargine)", 
                "intervention_name": "Insulin glargine", 
                "intervention_type": "Drug", 
                "other_name": "Lantus"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Sitagliptin", 
                "Insulin", 
                "Metformin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35233-1711"
                    }, 
                    "name": "Call for Information (Investigational Site 0450)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85016"
                    }, 
                    "name": "Call for Information (Investigational Site 0735)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92102"
                    }, 
                    "name": "Call for Information (Investigational Site 0750)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ventura", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93003"
                    }, 
                    "name": "Call for Information (Investigational Site 0468)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ventura", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93003"
                    }, 
                    "name": "Call for Information (Investigational Site 0457)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32207"
                    }, 
                    "name": "Call for Information (Investigational Site 0463)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami Lakes", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33014"
                    }, 
                    "name": "Call for Information (Investigational Site 0452)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "Call for Information (Investigational Site 0461)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30342"
                    }, 
                    "name": "Call for Information (Investigational Site 0741)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60643"
                    }, 
                    "name": "Call for Information (Investigational Site 0742)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Topeka", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66606"
                    }, 
                    "name": "Call for Information (Investigational Site 0737)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "Call for Information (Investigational Site 0465)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Call for Information (Investigational Site 0466)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Neptune", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07753"
                    }, 
                    "name": "Call for Information (Investigational Site 0470)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lake Success", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11042"
                    }, 
                    "name": "Call for Information (Investigational Site 0472)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lebanon", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37087"
                    }, 
                    "name": "Call for Information (Investigational Site 0473)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edinburg", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78539"
                    }, 
                    "name": "Call for Information (Investigational Site 0740)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76104"
                    }, 
                    "name": "Call for Information (Investigational Site 0456)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gary Jankelowitz", 
                    "phone": "61 2 8988 8246"
                }, 
                "facility": {
                    "address": {
                        "city": "North Ryde", 
                        "country": "Australia"
                    }, 
                    "name": "Merck Sharp & Dohme"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Medical Information Centre / Centre de l'information medicale de Merck Canada", 
                    "phone": "514-428-8600 / 1-800-567-2594"
                }, 
                "facility": {
                    "address": {
                        "city": "Kirkland", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H9H 3L1"
                    }, 
                    "name": "Merck Canada"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Maria Elena Azara Hernandez", 
                    "phone": "56 2 6558958"
                }, 
                "facility": {
                    "address": {
                        "city": "Santiago", 
                        "country": "Chile"
                    }, 
                    "name": "Merck Sharp & Dohme (I.A.) Corp."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Francesca Carvajal", 
                    "phone": "57 1219109011090"
                }, 
                "facility": {
                    "address": {
                        "city": "Bogota", 
                        "country": "Colombia"
                    }, 
                    "name": "MDS Colombia SAS"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Simona Martinkova", 
                    "phone": "420 233010213"
                }, 
                "facility": {
                    "address": {
                        "city": "Praha", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Merck Sharp and Dohme s.r.o."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gert Andersen", 
                    "phone": "45 44824475"
                }, 
                "facility": {
                    "address": {
                        "city": "Glostrup", 
                        "country": "Denmark"
                    }, 
                    "name": "Merck Sharp & Dohme"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Simona Martinkova", 
                    "phone": "36 1 457 8522"
                }, 
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "MSD Pharma Hungary Kft."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ofer Sharon", 
                    "phone": "972 9 9539310"
                }, 
                "facility": {
                    "address": {
                        "city": "Hod Hasharon", 
                        "country": "Israel"
                    }, 
                    "name": "Merck Sharp & Dohme Co. Ltd."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Patrizia Nardini", 
                    "phone": "39 06 361911"
                }, 
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy"
                    }, 
                    "name": "MSD Italia S.r.l."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Juan Marques", 
                    "phone": "52 55254819608"
                }, 
                "facility": {
                    "address": {
                        "city": "Mexico City", 
                        "country": "Mexico"
                    }, 
                    "name": "MSD"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Soraya Cedraro", 
                    "phone": "507-282-7200"
                }, 
                "facility": {
                    "address": {
                        "city": "Panama", 
                        "country": "Panama"
                    }, 
                    "name": "MSD CARD"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Cesar Recto", 
                    "phone": "632 784 9500"
                }, 
                "facility": {
                    "address": {
                        "city": "Makati", 
                        "country": "Philippines"
                    }, 
                    "name": "Merck Sharp & Dohme (I.A.) Corporation"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Maria Koroleva", 
                    "phone": "7 0959410000"
                }, 
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Merck Sharp & Dohme IDEA, Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Khanyi Mzolo", 
                    "phone": "27 11 655 3140"
                }, 
                "facility": {
                    "address": {
                        "city": "Midrand", 
                        "country": "South Africa"
                    }, 
                    "name": "MSD (Pty) LTD South Africa"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eran Gefen", 
                    "phone": "38 (044) 393 74 80"
                }, 
                "facility": {
                    "address": {
                        "city": "Kiev", 
                        "country": "Ukraine"
                    }, 
                    "name": "MSD Ukraine LLC"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Canada", 
                "Chile", 
                "Colombia", 
                "Czech Republic", 
                "Denmark", 
                "Hungary", 
                "Israel", 
                "Italy", 
                "Mexico", 
                "Panama", 
                "Philippines", 
                "Russian Federation", 
                "South Africa", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-dose Combination Tablet of Sitagliptin and Extended-release Metformin) in Pediatric Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline in hemoglobin A1c (A1C)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 20"
            }, 
            {
                "measure": "Number of participants who experienced at least one adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "up to 54 weeks"
            }, 
            {
                "measure": "Number of participants who discontinued study drug due to an adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 54 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01760447"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}